Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.2525 | 0.2555 | 0.1789 |
Brugia malayi | Hemopexin family protein | 0.2522 | 0.255 | 0.1779 |
Echinococcus multilocularis | adam 17 protease | 0.1511 | 0.0912 | 0.0912 |
Mycobacterium ulcerans | hydrolase | 0.2525 | 0.2555 | 0.5 |
Schistosoma mansoni | matrix metallopeptidase-7 (M10 family) | 0.2073 | 0.1823 | 0.5563 |
Brugia malayi | Matrixin family protein | 0.4595 | 0.5909 | 1 |
Loa Loa (eye worm) | matrixin family protein | 0.4595 | 0.5909 | 0.9987 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.4598 | 0.5914 | 1 |
Brugia malayi | Matrix metalloprotease, N-terminal domain containing protein | 0.2525 | 0.2555 | 0.1792 |
Mycobacterium leprae | PROBABLE HYDROLASE | 0.2525 | 0.2555 | 0.5 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.712 | 1 | 1 |
Onchocerca volvulus | Matrilysin homolog | 0.4598 | 0.5914 | 1 |
Loa Loa (eye worm) | matrixin family protein | 0.4598 | 0.5914 | 1 |
Onchocerca volvulus | 0.2522 | 0.255 | 0.1776 | |
Mycobacterium tuberculosis | Probable peptidoglycan hydrolase | 0.2525 | 0.2555 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.3175 | 0.3608 | 0.4363 |
Schistosoma mansoni | hypothetical protein | 0.2522 | 0.255 | 1 |
Echinococcus granulosus | adam 17 protease | 0.1662 | 0.1156 | 0.1156 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 175 uM | Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1995896 |
CC50 (functional) | = 175 uM | Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1995896 |
IC50 (functional) | 0 uM | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1; ; I = Inactive | ChEMBL. | 1995896 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.